目的 探討米非司酮聯(lián)合亮丙瑞林治療子宮肌瘤的臨床療效。方法 以回顧性研究的方法選取2015年7月-2018年7月漯河市郾城區(qū)中醫(yī)院88例子宮肌瘤患者為研究對象，根據(jù)不同的給藥方法將受試者進行分組，其中對照組44例患者接受亮丙瑞林治療，觀察組44例患者在對照組的基礎上聯(lián)合米非司酮治療，兩組均連續(xù)治療3個月。比較兩組患者的臨床療效、治療前后各性激素與血清細胞因子水平變化以及子宮與肌瘤體積變化。結果 觀察組的治療總有效率為93.18%，顯著高于對照組的77.27%（P<0.05）。治療后兩組患者孕激素（P）、雌二醇（E2）、促卵泡生長激素（FSH）、黃體生成激素（LH）等各性激素水平及基質(zhì)金屬蛋白酶-9（MMP-9）、胰島素樣生長因子（IGF-1）、腫瘤壞死因子-α（TNF-α）、表皮細胞生長因子（EGF）、超敏C反應蛋白（hs-CRP）等細胞因子水平較治療前均顯著降低（P<0.05），且觀察組均顯著低于對照組（P<0.05）。治療后兩組患者的子宮及肌瘤體積較治療前均顯著減小（P<0.05），且觀察組顯著小于對照組（P<0.05）。結論 米非司酮聯(lián)合亮丙瑞林可有效降低各性激素及血清細胞因子水平，改善患者的臨床癥狀及體征，療效確切，在子宮肌瘤治療中具有較高的應用價值。

Objective To explore clinical efficacy of mifepristone combined with leuprolide on patients with uterine fibroids.Methods Selecting the method of retrospective study,88 patients with uterine fibroids were selected as the subjects in our hospital from July 2015 to July 2018,Subjects are grouped according to different methods of administration.44 patients in the control group were treated with mifepristone,44 patients in the experimental group on the basis of this combination of leuprolide.The clinical efficacy,the changes of sex hormones and serum cytokines levels,and the changes of uterus and fibroid volume before and after treatmentwere compared between the two groups.Results The total effective rate of the study group were significantly higher than the control group (P<0.05).After treatment,the sex hormones and serum cytokines levels of the two groups were significantly reduced than those before treatment,and the study group was significantly lower than the control group (P<0.05).After treatment,the uterus and fibroid volume in the two groups were significantly reduced than those before treatment,and the study group was smaller than the control group (P<0.05).Conclusion Mifepristone combined with leuprolide can effectively reduce sex hormones and serum cytokines levels,improve the clinical symptoms and signs of patients,the curative effect is exact,which has high application value in the treatment of uterine fibroids.